PRISMA-guided trial selection (2019–2024) and CASP quality screening (≥9/13) yielded eight small RCTs spanning ONS and IDPN modalities with usual-care or placebo comparators. Random-effects pooling ...
A meta-analysis of six randomized trials found silymarin significantly lowered AST and ALT in chemotherapy patients, with no significant effect on ALP or total bilirubin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results